NASDAQ: LENZLenz Therapeutics Inc Stock
$23.82+0.76 (+3.3%)
Updated Apr 17, 2025
LENZ Price
$23.82
Fair Value Price
N/A
Market Cap
$656.07M
52 Week Low
$14.42
52 Week High
$38.93
P/E
-10.18x
P/B
3.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$49.77M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$59M
Beta
1.3
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LENZ Overview
Graphite Bio, Inc. is a clinical-stage company developing therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform enables the correction of mutations, the replacement of entire disease-causing genes with normal genes, or the insertion of new genes into predetermined, safe locations. Known as Integral Medicines, Inc. until 2020, Graphite Bio was incorporated in 2017 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LENZ's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LENZ
Ranked#114 of 463
Ranked#114 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important LENZ news, forecast changes, insider trades & much more!
LENZ News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LENZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LENZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LENZ is good value based on its book value relative to its share price (3.21x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
LENZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LENZ due diligence checks available for Premium users.
Valuation
LENZ fair value
Fair Value of LENZ stock based on Discounted Cash Flow (DCF)
Price
$23.82
Fair Value
$22.77
Overvalued by
4.59%
LENZ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LENZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.18x
Industry
-177.72x
Market
27.98x
LENZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.21x
Industry
4.05x
LENZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LENZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.7M
Profit Margin
0%
LENZ's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$215.3M
Liabilities
$11.2M
Debt to equity
0.06
LENZ's short-term assets ($211.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LENZ's short-term assets ($211.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LENZ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LENZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.1M
Investing
-$11.9M
Financing
$53.0k
LENZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LENZ vs Biotech Stocks
Lenz Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.